Delta4 partners in two main ways:
Learn more about ways to partner with Delta4 at https://delta4.ai/partnering/, as well as about our services at https://delta4.ai/services/.
Our Hyper‑C platform combines advanced data analytics with systems biology to power every stage of drug discovery. We help model disease pathobiology and drug mechanisms of action (MoA), identify and prioritize drug targets, enable drug- and disease‑centric repositioning, predict mechanistic adverse events, analyze drug combinations, evaluate MoA within standard‑of‑care treatments, and discover or prioritize biomarkers.
Learn more about our services at https://delta4.ai/services/.
A typical project focused on a single use case – such as drug repositioning (indication expansion), biomarker discovery, or target identification – takes about 4-6 months. Longer collaborations or framework agreements can be established to cover multiple use cases within specific therapeutic areas.
Learn more about our services at https://delta4.ai/services/.
Delta4 provides quality‑controlled data harmonization pipelines for biomedical research, hosts one of the largest collections of context‑aware molecular models for human diseases and drug mechanisms of action, and applies validated workflows for drug discovery using proprietary disease‑drug interference algorithms. Our flexible workflows are customized for each client and are supported by a multidisciplinary team of professionals with expertise in computational biology, bioinformatics, molecular biology, IT, pharma, and finance.
Learn more about Hyper-C at https://delta4.ai/hyper-c/, our services at https://delta4.ai/services/, and get to know the team at https://delta4.ai/team/.
Using our AI platform Hyper-C, we’ve identified new treatment options for focal segmental glomerulosclerosis (FSGS), a rare chronic kidney disease with no approved therapy. The drug assets are patent-protected, and a Phase II clinical trial plan has been developed with leading clinical experts.
Hyper-C has also uncovered potential new indications for the anti-inflammatory drug iguratimod. A detailed report is available along with a video overview of the process from drug mechanism of action modeling to phenotype screening and indication expansion.
Learn more about our success stories at https://delta4.ai/success-stories/ and find key scientific publications at https://delta4.ai/publications/.
Hyper-C (short for Hyper-Connectivity) is an AI-powered big data platform that analyzes biomarkers, drug targets, and drugs to improve understanding and treatment of human diseases. It models disease pathobiology and drug mechanisms at the molecular level to algorithmically identify potential matches between diseases and therapies.
Learn more about Hyper-C at https://delta4.ai/hyper-c/.
Hyper-C (short for Hyper-Connectivity) is an AI-powered big data platform that analyzes biomarkers, drug targets, and drugs to improve understanding and treatment of human diseases. It models disease pathobiology and drug mechanisms at the molecular level to algorithmically identify potential matches between diseases and therapies.
Learn more about Hyper-C at https://delta4.ai/hyper-c/.
Yes, Hyper‑C supports seamless integration of customer-specific data to improve the generation of disease and drug models across all use cases. It can incorporate various data types, including omics, biomarker, and compound screening data. Strict policies ensure secure handling of data of all types, including data from clinical trials.
Learn more about Hyper-C at https://delta4.ai/hyper-c/ our services at https://delta4.ai/services/.
AI is deeply integrated into the Hyper-C platform. It powers the creation of proprietary catalogs and controlled vocabularies, builds connections between entities in the Hyper-KG knowledge graph, and supports text summarization. Hyper-C’s LLM-RAG approach minimizes hallucinations for more reliable results.
Learn more about how Hyper-C is supported by AI at Hyper-C Site Link.
Rare diseases are a key part of Delta4’s platform and represent a large portion of the phenotype catalog. However, common diseases are also covered as we do not focus exclusively on rare conditions.
Learn more about diseases/phenotypes covered in Hyper-C at https://delta4.ai/hyper-c/.
The Hyper-C platform supports all therapeutic areas, enabling us to offer drug discovery services for any human disease. Our current development programs focus on cardiometabolic, renal, oncologic, central nervous system, and gastrointestinal disorders.
Learn more about diseases/phenotypes covered in Hyper-C at https://delta4.ai/hyper-c/ and learn more about Delta4’s development programs at https://delta4.ai/development-programs/.
Delta4 helps de-risk drug development for specific diseases through several approaches. Our network-based molecular models and network interference analysis support the prediction of potential adverse events and clarify drug mechanisms of action (MoA). We also identify predictive biomarkers to support responder selection and to monitor therapeutic effects at the molecular level. Additionally, our drug combination analyses compare a drug’s MoA with standard‑of‑care treatments to evaluate synergistic effects.
Learn more about the drug asset de-risking use case at https://delta4.ai/services/.
Delta4 uses its proven AI-driven systems biology platform Hyper-C to model how a compound works and then computationally screen it against a library of disease models. The highest-ranked disease indications are analyzed in detail to identify promising new uses for the compound, supported by clear mechanistic hypotheses on how it may benefit disease progression. This workflow can also begin with a specific drug target, including whether it should be inhibited or activated.
Learn more about the indication expansion use case at https://delta4.ai/services/.
Delta’s AI‑powered systems biology platform, Hyper‑C, identifies and ranks disease‑specific biomarkers by integrating diverse data — such as genetic associations, molecular mechanisms, disease regulation, and literature evidence. It supports the discovery of diagnostic and prognostic biomarkers as well as predictive markers to guide drug development and clinical trial design for optimized treatment outcomes.
Learn more about the biomarker identification use case at https://delta4.ai/services/.
Delta’s AI-driven systems biology platform, Hyper‑C, identifies and prioritizes drug targets for specific diseases by integrating diverse data — including disease regulation, genetic associations, literature evidence, molecular mechanisms, network centrality, and literature trends in both the molecule and its biological context.
Learn more about the drug target identification use case at https://delta4.ai/services/.
Delta4 facilitates patient stratification via biomarker identification, allowing for the identification of high-risk patients (prognostic markers) as well as patients likely to respond to therapy (predictive markers). By modeling potential side effects and using biomarkers to detect patients at risk for adverse events, Delta4 also improves patient recruitment, reduces development risks, and increases drug development efficiency and success rates.
Learn more about how Delta4 can support your clinical trials at https://delta4.ai/services/.
Delta4 uses Combo-C, a module of the Hyper-C software platform, to systematically screen for drug combinations with synergistic effects that target key disease pathways. Combo-C leverages network-based molecular models of disease biology and drug mechanisms of action available within the Hyper-C platform to reveal the most promising therapeutic synergies.
Learn more about the drug combination use case at Services Site Link.